How can our biologics drug discovery program move forward from hit-to-lead candidate faster?

We de-risk biologic development by providing the optimal early foundation. Seamlessly bridge from discovery into preclinical development & beyond with our integrated discovery services.

Enhanced Antibody Discovery Capabilities

Seamlessly navigate the complexity of hit-to-lead candidate selection with Abzena.

The hit-to-lead candidate selection process is a crucial step in biologic discovery. It signifies the end of the preclinical research stage and the beginning of clinical testing. Through an enhanced discovery process through our seamless partnership with Mabqi, we streamline critical component drug design, applying our enhanced approach to discovery, through development and manufacturing. Abzena ensures you select the best lead candidate.

At Abzena, we have over 20 years of experience in offering a comprehensive suite of discovery services that can rapidly progress your program and reduce time to market, whilst ensuring you select the best possible lead candidate.

Our strategic partnership with Mabqi’s combined offerings will leverage their LiteMab Antibody Discovery Studio for hit screening, characterization, and hit selection by using universal & pH-sensitive libraries to identify top lead candidates and utilize Abzena’s leading capabilities for developability assessment.

Through leveraging our combined hit-to-lead candidate expertise you can rapidly progress your program, reduce time to market, and ensure you have selected the best possible lead candidate to move forward.

Start Your Program

Supporting Complex Biologics Discovery

At Abzena we work with the future in mind. Why? Because we understand the challenges you will face at every milestone. We help you make informed decisions early that will simplify your programs pathway to market. Let’s start smart and finish fast.

Abzena offers a focused approach:

  • Fully integrated end-to-end biologics development partner with services that span early R&D through commercial capabilities
  • High-quality and trusted data that drives development to increase the likelihood of clinical and commercial success
  • Streamlined regulatory support tailored to your program to ensure successful IND or BLA filing

Antibody Discovery Services from Hit to Lead Candidate

Abzena Cambridge Chemistry Lab - Abzena

Essential to this program are:

  • Antibody Discovery (Partnership with Mabqi)
  • Biologics Design & Optimization
  • Bioconjugates Design & Optimization
  • Manufacturability Assessments
  • Immunogenicity Assessments
  • Functional Characterization
  • Research Material Generation
  • In vivo characterization (Via Oncodesign)

Leveraging Our 'Developability' Solution

We understand that drug development is a balancing act. When we are discovering and designing a drug, it means finding and balancing everything we would want in a perfect lead candidate with all that we face in reality.

So, how does Abzena allow you to start smart and finish fast through their ‘Developability’ solution? Click the link below to find out more or contact our experts.

 

Drug Developability: the Derisker
Abzena & Mabqi Announce Partnership to Offer Integrated Discovery through Development Solution - Abzena

Abzena & Mabqi Partnership: Integrated Discovery through Development Solution

Our partnership’s combined offerings will leverage Mabqi’s LiteMab Antibody Discovery Studio for hit screening, characterization, and hit selection by using universal & pH-sensitive libraries to identify top lead candidates, and utilize Abzena’s capabilities for developability, cell line development, process development, and GMP manufacturing. Both organizations have extensive expertise in supporting a broad range of modalities, including monoclonal antibodies (mAbs), mAb fragments, bi- and multi-specifics, and bioconjugates such as AOCs.

Find Out More

Biologics drug discovery requires client-driven and flexible specialties companies

We provide our customers with a unique ecosystem of premium expert support through our DRIVE-Biologics collaboration with Oncodesign Services.  DRIVE-Biologics leverages the skills and expertise to develop antibodies in oncology and inflammation through a privileged collaboration that combines Abzena’s discovery, development, and manufacturing support of biologics and ADCs with Oncodesign Services of optimization to lead selection of naked or pay-loaded preclinical candidates vs TPP.

For more information about this streamlined collaboration hit the link below to discover DRIVE-Biologics.

Drive-Biologics

Latest News& Insights

Articles

PharmaSource: CDMO Industry Leaders on Resilience, Capability Gaps, & the Partnerships That Will Define the Next Decade

Read More

Articles

BioPharm International: Using Risk-Based Quality Frameworks to Fast-Track Biopharma Development: A Q&A with Abzena’s Dr. Jeffrey C. Mocny

Read More

Articles

Outsourced Pharma: Why Life Cycle Integration Is Critical To ADC And XDC Success

Read More

Together, we can keep moving medicine forward.

The leading biologics CDMO + CRO that accelerates drug development, moving medicine forward for patients in need.